Diabetes, obesity & metabolism · 2025
Plasma proteomics identifies potential drug targets for diabetic polyneuropathy: Evidence from prospective cohorts and genetic analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lan Haoning, Xu Songchao, Li Huili, Guo Ruijuan, Ma Danxu, Feng Zhong, Wang Yun
Аннотация
AIMS: Effective, targeted drug therapies for diabetic polyneuropathy (DP) are currently lacking. This study was designed to pinpoint new drug targets to enhance treatment efficacy.
MATERIALS AND METHODS: Using large-scale clinical and genetic datasets, we scrutinised proteins potentially involved in the onset and progression of DP. We further probed their associations with clinical symptoms and risk factors, and explored potential pathogenic mechanisms via single-cell sequencing.
RESULTS: We identified six proteins linked to DP, with Tumour Necrosis Factor Receptor Superfamily Member 14 (TNFRSF14) standing out as a particularly compelling target. Notably, TNFRSF14 levels correlated with clinical scale (as assessed by the Michigan Neuropathy Screening Instrument) and might mediate the impact of metabolic syndrome on DP. At the cellular level, single-cell sequencing hinted that TNFRSF14 could drive DP progression by activating macrophages and compromising endothelial cell function.
CONCLUSIONS: TNFRSF14 emerges as a promising biomarker and therapeutic target for the early detection and specific treatment of DP, paving the way for improved patient outcomes.
MATERIALS AND METHODS: Using large-scale clinical and genetic datasets, we scrutinised proteins potentially involved in the onset and progression of DP. We further probed their associations with clinical symptoms and risk factors, and explored potential pathogenic mechanisms via single-cell sequencing.
RESULTS: We identified six proteins linked to DP, with Tumour Necrosis Factor Receptor Superfamily Member 14 (TNFRSF14) standing out as a particularly compelling target. Notably, TNFRSF14 levels correlated with clinical scale (as assessed by the Michigan Neuropathy Screening Instrument) and might mediate the impact of metabolic syndrome on DP. At the cellular level, single-cell sequencing hinted that TNFRSF14 could drive DP progression by activating macrophages and compromising endothelial cell function.
CONCLUSIONS: TNFRSF14 emerges as a promising biomarker and therapeutic target for the early detection and specific treatment of DP, paving the way for improved patient outcomes.